Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Maraviroc Unanimously Recommended For Accelerated Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

However, members of FDA’s Antiviral Drugs Advisory Committee voice numerous concerns, recommending additional data or analysis for full approval of the CCR5 antagonist.

You may also be interested in...



Pfizer’s Selzentry Wins FDA Approval For HIV

First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.

Pfizer’s Selzentry Wins FDA Approval For HIV

First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.

Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists

Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel